India to United States Of America: Bortezomib Export Trade Route

The India to United States Of America Bortezomib corridor is one of India's established pharmaceutical export routes, with 3 shipments documented worth a combined $209.6K USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 70% of all export value, reflecting the consolidated nature of India's bortezomib manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $69.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 76% of all shipments, consistent with bortezomib's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 23.4%, placing it at rank #8 among India's top bortezomib export destinations globally.

On the import side, key buyers of Indian bortezomib in United States Of America include EUGIA US LLC, XXOTEXXINCXX SIXXET. EUGIA US LLC is the single largest importer with 2 shipments valued at $145.9K USD.

India's bortezomib exports to United States Of America are driven primarily by a handful of large-scale manufacturers. EUGIA PHARMA SPECIALITIES LIMITED with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in United States Of America benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, GLAND PHARMA LIMITED — together account for 100% of total trade value on this route. The average shipment value of $69.9K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as bortezomib inj 3.5mg 10ml usa and bortezomib for injection 3.5 mg/ vial (bortezomib for injection 3.5mg/vial (sdv)- us (1 s pack)), suggesting that buyers in United States Of America tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, EUGIA US LLC is the largest importer with 2 shipments worth $145.9K USD — representing 70% of all bortezomib imports from India on this route.